MS disease-modifying therapies: injections, PML risk and lab monitoring

What these drugs do and how they are grouped

Disease-modifying therapies aim to prevent exacerbations and slow accumulation of disability; they do not treat an acute relapse, which is usually managed with corticosteroids. They are grouped by efficacy. Moderately effective options include interferon beta, glatiramer acetate, teriflunomide, fumarates and sphingosine 1-phosphate modulators such as fingolimod. Highly effective options include natalizumab, ocrelizumab and other antibodies.

Choice is made with the patient through shared decision-making with an MS specialist, balancing efficacy, route, monitoring burden and risk. For nursing, the useful grouping is by what can go wrong: injection and flu-like effects, infection and brain infection risk, heart rhythm changes, and liver or blood count changes.

Self-injected therapies: technique and side effects

Interferon beta and glatiramer are self-injected. Teach aseptic technique, site rotation, sharps disposal and recognition of site reactions. Interferon commonly causes flu-like symptoms such as fever, chills, aching and tiredness after injection, and the prescriber may suggest a pain or fever reliever. Alcohol can make interferon side effects worse.

Interferon also requires attention to mood: new or worsening depression or thoughts of self-harm need urgent reporting. Ask about bruising, bleeding and symptoms of liver or thyroid problems. Glatiramer can cause a reaction shortly after injection with flushing, chest discomfort, palpitations, anxiety or breathlessness; teach patients to seek emergency help if breathing or swallowing is affected.

Practical tips improve adherence. Allowing a refrigerated pen to reach room temperature as the product instructions describe, rotating through a written site plan and taking the dose at a consistent time of day can make injections more tolerable. Ask what the patient finds hardest, because missed doses are often due to fear, fatigue or site soreness rather than forgetting.

Natalizumab and PML risk

Natalizumab blocks white cells from crossing the blood-brain barrier. It carries a boxed warning for progressive multifocal leukoencephalopathy, an opportunistic brain infection caused by JC virus that usually leads to death or severe disability. Risk rises with anti-JCV antibodies, longer treatment and prior immunosuppressant use, and it is prescribed through a restricted programme.

Teach patients and families to report new or worsening weakness, clumsiness, vision change, speech difficulty, confusion or personality change, since these may be PML rather than a typical relapse. Observe during infusions and afterwards as the label requires, because hypersensitivity can occur. Herpes infections and significant liver injury are further warnings; report jaundice or dark urine.

Fingolimod, B-cell therapies and lab monitoring

Fingolimod can slow the heart, especially within six hours and up to 24 hours after the first dose, so first-dose monitoring is planned. It can also affect vision through swelling at the back of the eye; report blurring, shadows or a blind spot. Infections and PML are concerns with fingolimod and with B-cell therapies such as ocrelizumab.

Before ocrelizumab, hepatitis B history is checked, and vaccine timing is planned because some vaccines should be given before treatment. Across the class, follow the prescribed schedule of blood counts, liver tests and JC virus antibody testing, which may be repeated during treatment. Report fever, persistent infection or abnormal results rather than giving the next dose automatically.

Worked exam-style scenario

Imagine a hypothetical patient who has received natalizumab for several years and has a positive anti-JCV antibody result. A family member reports a few weeks of progressive clumsiness in one hand and new difficulty finding words. Options include reassuring that this is a usual relapse, giving the next infusion as scheduled, suggesting more rest, or holding the infusion and escalating for urgent evaluation.

Holding and escalating is the strongest answer because duration of therapy and antibody status raise PML risk, and new cognitive or motor deficits warrant urgent assessment. Assuming a relapse delays diagnosis. A second item asks what to monitor after a first fingolimod dose; heart rate and rhythm is the answer, not blood glucose.

Sources and further reading

DailyMed: TYSABRI (natalizumab) prescribing information. PML boxed warning and risk factors, restricted prescribing programme, infusion observation, herpes infections and hepatotoxicity.

MSD Manual Professional: Multiple sclerosis. Disease-modifying therapy efficacy groups, injectable and oral agents, PML risk ranking and JC virus antibody testing.

MedlinePlus: Interferon beta-1a subcutaneous injection. Flu-like symptoms after injection, alcohol, depression and self-harm warning, and blood and liver history.

MedlinePlus: Fingolimod. Heart rate slowing after the first dose and vision changes requiring report.